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RALPP could significantly increase
the FLR by a median of 62.3% (range, 53.1%–
95.4%) in a much shorter length of time
(mean = 21.8 ± 9.4 days) than by PVE, which
increased the FLR by a median of 24.6%
(range, 8.4%–35.4%) after 55.4 ± 15.6 days,
reflecting a significant gain of FLR by 38.0%
(P = 0.0079) with a significant reduction of
34 days to achieve this (P= 0.003) (Figs. 1, 2).
There was no difference in liver function
between the 2 groups on days 1 to 5 pos-
thepatectomy.
ALPPS is superior to PVE in terms of
FLR but is associated with a greater morbid-
ity and mortality, particularly from bile leaks
and hemorrhage after the initial procedure.4–8
In the current RALPP study, a high hyper-
trophy rate of 62.3%, similar to ALPPS,4,5
was achieved with no mortality and a mor-
bidity rate of 20.0%. No bile leaks were seen
in patients on liver resection after RALPP.
The hypertrophy rate is far greater than that
reported in PVE studies and, indeed, in this
case-controlled study, where the FLR was an-
alyzed with the same method of volume cal-
culation. The physiological mechanism for
this greater increase in FLR is not known but
may be in response to surgical trauma and
a complete transection of the parenchyma,
thereby stopping any cross-portal circulation.
Both these mechanisms may create a regen-
eration stimulus. The rapid regeneration re-
sponse of a mean of 21.8 days in our study and
9 days in the original ALPPS article has cer-
tain benefits.5 Importantly, there is less time
for additional micro- and macro-metastatic
diseases to develop. Indeed, in 12.0% of pa-
tients, hepatic resection after PVE is not pos-
sible due to tumor progression,3 thought to
FIGURE 1. The percentage increase in the
size of the FLR after both RALPP and PVE
(median, error bars depict the range).
∗∗P = 0.0079, calculated using the Mann-
Whitney U test.
FIGURE 2. The number of days between
either RALPP or PVE and completion hep-
atectomy (median, error bars depict the
standard deviation. ∗∗P = 0.003, calcu-
lated using the Student t test (2-tailed).
be due to a more rapid growth of tumor than
liver parenchyma after PVE.11 Whether this
is significantly improved with ALPPS must
be determined in an awaited clinical trial. The
major drawback to ALPPS is the high mor-
bidity rate, in particular from bile leaks, and
an increased mortality rate. We believe that
RALPP is a better alternative than ALPPS
because it limits the invasiveness of the first
stage of the procedure while capitalizing on
the liver hypertrophy without high morbidity
and mortality rates associated with ALPPS.
It can easily be performed laparoscopically
and can be performed at the same time as a
stage 1 liver resection for patients with bilobar
disease.
Although only 5 patients were reported
here who had undergone RALPP, it has been
demonstrated that it is a feasible and safe al-
ternative to ALPPS to achieve a rapid liver re-
generation in the contralateral lobe of the liver
without the increased morbidity and mortal-
ity associated with ALPPS. We are setting up
a randomized controlled trial to further eval-
uate the technique compared with PVE and
ALPPS.
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Reply:
W e present 3 letters to the editor in re-sponse to an original contribution by
Schnitzbauer et al.1 This inaugural article
introduced a novel method to induce liver
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hypertrophy of the liver remnant for patients
with extensive tumor load by performing
surgery in 2 stages with ligation of the right
portal vein and parenchymal transection, to-
gether with cleaning of tumors from the left
side of the liver in a first stage, followed in
a second stage by the completion hepatec-
tomy of the right side. The operation has be-
come known as “ALPPS” (Associating Liver
Partition with Portal vein ligation for Staged
hepatectomy).2 ALPPS has attracted intense
interest, as reflected by a series of letters pub-
lished in the journal3–6 and other case re-
ports published elsewhere.7–12 The discussion
has focused on the safety of the procedure
because of reported higher mortality and mor-
bidity rates than those reported by conven-
tional approaches.13,14 Three letters propos-
ing modifications to the initial ALPPS
procedure with the goal to increase safety and
avoid postoperative liver failure are presented.
The letter by Lau et al is based on the
hypothesis that the rapid volume increase in
ALLPS does not represent function and that
a functional assessment of the liver remnant
as a “safety check” could prevent postoper-
ative liver dysfunction and mortality. They
intraoperatively assessed function of the iso-
lated liver remnant using indocyanine green
clearance (ICG) of the liver remnant during
stages 1 and 2 by clamping the right hep-
atic artery and the right portal vein. They
observed that 2 weeks after stage 1, ICG
clearance of the liver remnant improves from
values considered to be unsafe for liver resec-
tion to acceptable values. The authors do not
explain, however, how they select their intra-
operative threshold of ICG retention of 4.8%
at 15 minutes to safely proceed with resec-
tion. We know from existing literature that, in
cirrhotic livers, a rate of retention of ICG of
less than 14% at 15 minutes is acceptable to
proceed with removal of more than 50% liver
tissue.15 Which cutoff offers the potential to
abort the completion hepatectomy at stage 2
resection, and thereby prevent liver failure,
remains unclear in this report of 1 case. Al-
though the method holds promise, there re-
mains some doubt about standardization be-
cause ICG clearance depends on portal flow,
which may vary considerably intraoperatively
and, moreover, has not been validated in the
setting of ALPPS.
Two other letters recommend techni-
cal modifications to ALPPS to improve safety
of the procedure. Gall et al propose to re-
place parenchymal transection during stage
1 with the use of lined up laparoscopic
radio-frequency probes to produce a necro-
sis zone of 1 cm width. This approach used
in 5 patients induced rapid hypertrophy in
the range of those observed in the standard
ALPPS approach. They label this modifi-
cation “RALPP” (Radio-frequency–Assisted
Liver Partition with Portal vein ligation).
They were able to complete both stages la-
paroscopically with no mortality. On the same
line, Gringeri et al report the use of microwave
ablation for stage 1, also performed laparo-
scopically, to create a “necrotic groove” be-
tween the right and left sides of the liver by
repeated and stepwise application in 1 pa-
tient. They observed a doubling of the liver
remnant in 10 days and performed stage 2
with only minor complications. They nick-
named their procedure “LAPS” (associating
Laparoscopic microwaveAblation withPortal
vein ablation for Staged hepatectomy). The
authors of both letters mention that they will
proceed with a prospective evaluation of their
modifications.
Although these concepts appropriately
look for improved safety in the procedure,
including the element of laparoscopy, we
would like to highlight a few points. First,
the promises of safety in case reports or
small series could easily be disappointed in
larger prospective studies. Second, authors
are tempted to draw early mechanistic con-
clusions about rapid growth simply because
vascular flow between the 2 liver sides is ab-
rogated in ALPPS, and also in RALPP and
LAPS, although this might not be the full
story. Other mechanisms boosting regenera-
tion, under investigation in a few laboratories,
may be involved. While we enthusiastically
welcome the new members into the ALPPS
family, we should focus now on investigat-
ing the underlying mechanisms behind this
rapid hypertrophy and from such knowledge
develop new and safer strategies.
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